{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T21:49:01Z","timestamp":1769982541393,"version":"3.49.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1136\/ard-2023-225074","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:20:34Z","timestamp":1700590834000},"page":"e7-e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response to: Correspondence on \u2018ACR\/EULAR antiphospholipid syndrome classification criteria\u2019 by Damoiseaux and van Beers"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-7696","authenticated-orcid":false,"given":"Medha","family":"Barbhaiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9326-6881","authenticated-orcid":false,"given":"Stephane","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-677X","authenticated-orcid":false,"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-225074_bib1","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1136\/ard-2023-225067","article-title":"Correspondence on \u201cLaboratory criteria in the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: a critical appraisal\u201d by Barbhaiya et al","volume":"83","author":"Damoiseaux","year":"2024","journal-title":"Annals Rheum Dis"},{"key":"10.1136\/ard-2023-225074_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225074_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-225074_bib4","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1136\/ard-2023-225054","article-title":"Response to: correspondence on \u201c2023 ACR\/EULAR APS classification criteria\u201d by Miro-Mur et al","volume":"83","author":"Erkan","year":"2024","journal-title":"Annals Rheum Dis"},{"key":"10.1136\/ard-2023-225074_bib5","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/ard-2023-225042","article-title":"Correspondence on \u20182023 ACR\/EULAR antiphospholipid syndrome classification criteria' by Barbhaiya et al","volume":"83","author":"Miro-Mur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-225074_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002099","article-title":"Multi-center study to improve clinical interpretation of rheumatoid factor and anti-Citrullinated protein\/peptide antibodies test results","volume":"8","author":"Van Hoovels","year":"2022","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-225074_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.15585","article-title":"Semiquantitative interpretation of Anticardiolipin and Anti\u03b22Glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC subcommittee on Lupus anticoagulant\/Antiphospholipid antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2023-225074_bib8","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jth.15785","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC subcommittee on Lupus anticoagulant\/Antiphospholipid antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2023-225074_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0002-9343(99)80014-X","article-title":"Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus","volume":"98","author":"Escalante","year":"1995","journal-title":"Am J Med"},{"key":"10.1136\/ard-2023-225074_bib10","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria of the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2023-225074_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1136\/ard-2023-225074_bib12","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jth.12264","article-title":"Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile","volume":"11","author":"Pengo","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1136\/ard-2023-225074_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-225074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:19:58Z","timestamp":1749806398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0003496724003777"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-225074","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to: Correspondence on \u2018ACR\/EULAR antiphospholipid syndrome classification criteria\u2019 by Damoiseaux and van Beers","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-225067","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}